Anti-Human CD279 (PD-1) (Nivolumab) [Clone 5C4.B8] — APC
Anti-Human CD279 (PD-1) (Nivolumab) [Clone 5C4.B8] — APC
Product No.: LT1203
Product No.LT1203 Clone 5C4.B8 Target PD-1 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1 Isotype Human IgG1κ Applications FC , IHC |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human PD-1 Product Concentration 0.2 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (650 nm) RRIDAB_2893894 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IHC FA Additional Reported Applications For Relevant Conjugates ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only. Background Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects. Antigen Distribution PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. Ligand/Receptor PD-L1 and PD-L2 PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Costimulatory Molecules . Immuno-Oncology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Nivolumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) ELISA assays by serving as the known concentration samples that establish the standard curve, which is then used to quantify Nivolumab levels in serum samples of patients. In a PK bridging ELISA for Nivolumab:
In summary: Standard flow cytometry protocols using a PE or APC-conjugated Nivolumab biosimilar are designed to quantify PD-1 expression levels and confirm binding capacity directly on the cell surface, particularly for human immune cells such as T lymphocytes. These protocols are typically used in clinical and preclinical research to assess immune checkpoint blockade effectiveness or to validate reagents for immunomonitoring. Protocol Overview:
Core Procedure Steps:
Special Notes and Best Practices:
References to Protocol Details:
This approach is a gold-standard for validating PD-1 expression and confirming Nivolumab biosimilar binding and functionality in immunophenotyping and drug development contexts. Biopharma companies perform a comprehensive set of analytical assays to confirm that a proposed biosimilar is structurally and functionally similar to the originator (reference) drug. These include highly sensitive, orthogonal (complementary) methods targeting all relevant critical quality attributes (CQAs). Typical Analytical Assays Performed:
Workflow:
Leinco Biosimilars in Analytical Studies: The search results do not specifically reference Leinco’s biosimilar products. Based on industry practice and Leinco’s reputation as a supplier of high-quality reagents (including biosimilar antibodies for research use), it is likely that Leinco biosimilars are used as control materials, reference standards, or test articles in analytical comparability assays. Such biosimilars may be employed for:
This role would be based on their quality and characterization, but unless explicitly cited in study protocols or regulatory filings, Leinco biosimilars themselves are generally not submitted as clinical biosimilar products for regulatory approval. Instead, they serve mainly as well-characterized, representative materials for robust, reproducible assay development and comparative analysis. If a more specific application of Leinco biosimilars in regulatory submissions or pivotal biosimilarity studies is required, direct information from Leinco or cited regulatory filings would be necessary. References & Citations1. Minato, N. et al. (2002) Proc Natl Acad Sci U S A. 99(19): 12293–97. 2. Korman, AJ. et al. (2014) Cancer Immunol Res. 2(9):846-56. 3. Li, Y. et al. (2016) MAbs. 8(5):951-60. 4. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1200 | |
LT1203 | |
LT1204 | |
LT1211 | |
LT1205 |
